Biotronik has announced that the first patient in the United States has been implanted with the company’s Lumax 740 dual-chamber implantable cardioverter defibrillator (ICD).
“Patients on anti-arrhythmic medication may have slower ventricular tachycardias, which can influence a patient’s haemodynamics and directly affect a device’s ability to discriminate arrhythmias and successfully restore a normal rhythm,” said Larry A Chinitz, director, Cardiac Electrophysiology, Invasive Cardiology at the NYU Heart Rhythm Center, NYU School of Medicine. “In addition, the presence of atrial arrhythmias can confuse the device if it is not able to tell the difference between a lethal arrhythmia and a non-lethal arrhythmia.”
Lumax 740 has a unique feature, called Smart detection, which aids in rhythm discrimination and reduces unnecessary therapies. It continues to discriminate between atrial and ventricular arrhythmias, with a high level of specificity, even when an arrhythmia is redetected. Reducing unnecessary therapies also reduces the risk for long-term medical consequences that may result from inappropriate shocks.